Literature DB >> 25147884

Treatments for idiopathic pulmonary fibrosis.

Talmadge E King, Paul W Noble, Williamson Z Bradford.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25147884     DOI： 10.1056/NEJMc1407776

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

1.  Self-assembled Micelle Interfering RNA for Effective and Safe Targeting of Dysregulated Genes in Pulmonary Fibrosis.

Authors:  Pyoung Oh Yoon; Jin Wook Park; Chang-Min Lee; Sung Hwan Kim; Han-Na Kim; Youngho Ko; Seon Joo Bae; Sungil Yun; Jun Hong Park; Taewoo Kwon; Woo Seok Kim; Jiyoung Lee; Qing Lu; Hye-Ryun Kang; Won-Kyung Cho; Jack A Elias; Joo-Sung Yang; Han-Oh Park; Kyuhong Lee; Chun Geun Lee
Journal:  J Biol Chem       Date:  2016-01-27       Impact factor: 5.157

2.  Therapeutic targeting of argininosuccinate synthase 1 (ASS1)-deficient pulmonary fibrosis.

Authors:  Ji-Min Li; David C Yang; Justin Oldham; Angela Linderholm; Jun Zhang; Jun Liu; Nicholas J Kenyon; Ching-Hsien Chen
Journal:  Mol Ther       Date:  2021-01-26       Impact factor: 11.454

3.  Regulation and role of the ER stress transcription factor CHOP in alveolar epithelial type-II cells.

Authors:  Andreas Guenther; Martina Korfei; Oleksiy Klymenko; Martin Huehn; Jochen Wilhelm; Roxana Wasnick; Irina Shalashova; Clemens Ruppert; Ingrid Henneke; Stefanie Hezel; Katharina Guenther; Poornima Mahavadi; Christos Samakovlis; Werner Seeger
Journal:  J Mol Med (Berl)       Date:  2019-04-26       Impact factor: 4.599

4.  A homozygous SFTPA1 mutation drives necroptosis of type II alveolar epithelial cells in patients with idiopathic pulmonary fibrosis.

Authors:  Akio Takezaki; Shin-Ichi Tsukumo; Yasuhiro Setoguchi; Julie G Ledford; Hisatsugu Goto; Kazuyoshi Hosomichi; Hisanori Uehara; Yasuhiko Nishioka; Koji Yasutomo
Journal:  J Exp Med       Date:  2019-10-10       Impact factor: 14.307

5.  Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.

Authors:  Siri T Lehtonen; Anniina Veijola; Henna Karvonen; Elisa Lappi-Blanco; Raija Sormunen; Saara Korpela; Ulrika Zagai; Magnus C Sköld; Riitta Kaarteenaho
Journal:  Respir Res       Date:  2016-02-04

6.  Living with Fibrosis: From Diagnosis to Future Hope.

Authors:  Matthew A Sleeman; Joseph Parker; Lynne A Murray
Journal:  Front Pharmacol       Date:  2015-12-16       Impact factor: 5.810

7.  Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis.

Authors:  Corina N D'Alessandro-Gabazza; Taro Yasuma; Tetsu Kobayashi; Masaaki Toda; Ahmed M Abdel-Hamid; Hajime Fujimoto; Osamu Hataji; Hiroki Nakahara; Atsuro Takeshita; Kota Nishihama; Tomohito Okano; Haruko Saiki; Yuko Okano; Atsushi Tomaru; Valeria Fridman D'Alessandro; Miyako Shiraishi; Akira Mizoguchi; Ryoichi Ono; Junpei Ohtsuka; Masayuki Fukumura; Tetsuya Nosaka; Xuenan Mi; Diwakar Shukla; Kensuke Kataoka; Yasuhiro Kondoh; Masaki Hirose; Toru Arai; Yoshikazu Inoue; Yutaka Yano; Roderick I Mackie; Isaac Cann; Esteban C Gabazza
Journal:  Nat Commun       Date:  2022-03-23       Impact factor: 14.919
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.